SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at SMS Pharmaceuticals’ exclusive testing facility

09 Mar 2020 Evaluate

The United States Food and Drug Administration (USFDA) has successful completed regulatory inspection at SMS Pharmaceuticals’ exclusive testing facility during March 02, 2020 to March 06, 2020. The regulatory audit resulted in zero observation.

The company is committed to meeting the highest quality standards and is further committed to full compliance with CGMP & GLP regulations at all its manufacturing & Analytical facilities. The 'Central Laboratory Analytical Services' is company’s independent testing laboratory, and this was the first USFDA inspection concluded with zero observations.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×